M2 macrophages mediate sorafenib resistance by secreting HGF in a feed-forward manner in hepatocellular carcinoma

BACKGROUND: Sorafenib is the only approved first line systemic therapy for advanced hepatocellular carcinoma (HCC) in the last decade. Tumour resistance to sorafenib has been of major obstacles to improve HCC patient survival. METHODS: We polarised THP-1 cells to M1 and M2 macrophages, performed var...

Descripción completa

Detalles Bibliográficos
Autores principales: Dong, Ningning, Shi, Xiangyi, Wang, Suihai, Gao, Yanjun, Kuang, Zhenzhan, Xie, Qian, Li, Yonglong, Deng, Huan, Wu, Yingsong, Li, Ming, Li, Ji-Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2019
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738111/
https://www.ncbi.nlm.nih.gov/pubmed/31130723
http://dx.doi.org/10.1038/s41416-019-0482-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6738111/
https://www.ncbi.nlm.nih.gov/pubmed/31130723
http://dx.doi.org/10.1038/s41416-019-0482-x

Ejemplares similares